MyFinsight
Home
Blog
About
Context Therapeutics Inc. (CNTX)
Context Therapeutics Inc. (CNTX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$11,538,225
Free Cash flow
-$7,038,225
Unit: Dollar
Positive Cash Flow Breakdown
Acquired in-process research and...
Prepaid expenses and other curre...
Accounts payable
Others
Negative Cash Flow Breakdown
Acquired in-process research and...
Accrued expenses and other curre...
Operating lease liability
Purchase of property and equipme...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-14,558,426
-8,680,572
-13,025,607
-9,693,237
Acquired in-process research and development charge
-
-
-
0
Research and development expense, acquired in process
-
-
2,000,000
-
Acquired in-process research and development charge
6,500,000
-
-
-
Share-based compensation expense
528,102
409,220
325,168
323,081
Depreciation and amortization expense
6,647
4,687
4,065
4,066
Reduction in the carrying amount of operating lease right-of-use asset
38,826
31,418
28,212
27,457
Prepaid expenses and other current assets
-1,159,729
1,629,746
237,840
-1,310,554
Accounts payable
822,480
-67,158
-187,989
324,996
Accrued expenses and other current liabilities
-1,479,663
-1,466,525
2,179,172
1,151,338
Operating lease liability
-37,432
-30,698
-28,136
-27,119
Net cash used in operating activities
-7,019,737
-11,429,374
-8,942,955
-6,578,864
Acquired in-process research and development
4,500,000
-
2,000,000
0
Purchase of property and equipment
18,488
37,258
0
0
Net cash used in investing activities
-4,518,488
-37,258
-2,000,000
0
Proceeds from the sale of common stock and prefunded warrants in private placement, net of offering costs
-
-
0
-
Payment of offering costs from the sale of common stock from atm facility
0
0
0
15,268
Net cash used in financing activities
0
0
0
0
Net decrease in cash and cash equivalents
-11,538,225
-11,466,632
-10,942,955
-6,578,864
Cash and cash equivalents at beginning of period
54,528,596
65,995,228
76,938,183
94,429,824
Cash and cash equivalents at end of period
42,990,371
54,528,596
65,995,228
76,938,183
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net decrease in cash
and cash...
-$11,538,225
(-5.73%↓ Y/Y)
Acquired in-process
research and development...
$6,500,000
Prepaid expenses and
other current assets
-$1,159,729
(-3216.16%↓ Y/Y)
Accounts payable
$822,480
(-14.23%↓ Y/Y)
Share-based compensation
expense
$528,102
(-22.66%↓ Y/Y)
Reduction in the carrying
amount of operating...
$38,826
(-26.38%↓ Y/Y)
Depreciation and
amortization expense
$6,647
(-18.14%↓ Y/Y)
Net cash used in
operating activities
-$7,019,737
(35.38%↑ Y/Y)
Net cash used in
investing activities
-$4,518,488
(-13210.03%↓ Y/Y)
Canceled cashflow
$9,055,784
Net loss
-$14,558,426
(-8.61%↓ Y/Y)
Acquired in-process
research and development
$4,500,000
Purchase of property and
equipment
$18,488
(-45.54%↓ Y/Y)
Accrued expenses and
other current...
-$1,479,663
(-272.93%↓ Y/Y)
Operating lease liability
-$37,432
(28.10%↑ Y/Y)
Buy us a coffee